Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

1 year ago

CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as…

American Oncology Network (AON) and Vantage Health Technologies Partner to Improve Cancer Patient Outcomes with AI-enabled Value-Based Care Platform

1 year ago

American Oncology Network (AON) and Vantage Health Technologies Partner to Improve Cancer Patient Outcomes with AI-enabled Value-Based Care Platform Todd…

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

1 year ago

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome…

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

1 year ago

Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous…

Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy

1 year ago

LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA)…

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

1 year ago

IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its…

CareMed Has Been Selected as a National Specialty Pharmacy Partner for Lecanemab-irmb (Leqembi®)

1 year ago

NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by…

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

1 year ago

DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in…

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

1 year ago

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and…